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Available online 10 May 2016Background: Few studies have systematically investigated insomnia in adults with epilepsy.
Methods:Weperformed a prospective cross-sectional investigation of the prevalence, severity, and comorbidities
of insomnia in 90 adults with epilepsy using a battery of self-reported instruments and polysomnography. We
quantiﬁed insomnia severity using the Insomnia Severity Index (ISI).
Results: Fifty-nine of 90 (65.5%) adults with epilepsy reported insomnia (ISI ≥ 8), moderate or severe (ISI ≥ 15) in
28.9%. Good agreement between standard clinical diagnostic criteria and ISIwas found for patientswith ISI scores
b8 and ≥15. Scores on the modiﬁed Beck Depression Inventory (mBDI) (r = 0.25, p = 0.021), the original BDI
(r = 0.32, p = 0.002), and self-reported total sleep duration (TSD) (r =−0.3, p = 0.006) were signiﬁcantly
related to ISI score. Amultiple regressionmodel found that decreased TSD (ß=−0.93, p= 0.007), head trauma
(ß=4.37, p=0.003), sedative–hypnotic use (ß=4.86, p=0.002), AEDpolytherapy (ß=3.52, p=0.005), and
asthma/COPD (ß= 3.75, p = 0.014) were predictors of a higher ISI score. For 63 patients with focal epilepsy, an
increased mBDI (ß = 0.24, p = 0.015), decreased TSD (ß =−1.11, p = 0.008), asthma/COPD (ß = 4.19, p =
0.02), and epilepsy surgery (ß = 5.33, p = 0.006) were signiﬁcant predictors of an increased ISI score. Patients
with temporal lobe epilepsy (TLE) showed a trend for greater severity compared with those with extra-TLE
(ß =−2.92, p = 0.054).
Conclusions:Our ﬁndings indicate that severity of insomnia in adults with epilepsy ismore likely to be associated
with comorbid medical and depressive symptoms and less likely to be directly related to epilepsy. Good
agreement between standard clinical diagnostic criteria for insomnia and the ISI for subjects without insomnia
symptoms and for those with moderate-to-severe symptoms supports the use of this instrument in epilepsy
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Insomnia Severity Index1. Introduction
Sleep and epilepsy are common but often poor bedfellows. Sleep
disorders are two to three times more common in adults with epilepsy
compared with those in general age-matched populations [1–4]. The
few prospective studies that have examined sleep complaints in adults
with epilepsy have identiﬁed sleep maintenance insomnia (difﬁculty
staying asleep) as the most common sleep/wake complaint in adults
with epilepsy. The few prospective studies examining the complaint of
insomnia in adults with epilepsy have been based primarily on self-
reported sleep questionnaires [1,3,5–9].ue,
license (To better understand the prevalence, severity, and comorbidities of
insomnia in adults with epilepsy, we chose to systematically study it
using structured interviews and a battery of validated self-reported
questionnaires including the Insomnia Severity Index (ISI) [10] and per-
formed in-laboratory video-polysomnography (PSG) with 18-channel
EEG to identify undiagnosed obstructive sleep apnea (OSA).
2. Materials and methods
2.1. Study population
We prospectively enrolled consecutive adults (≥18 years) with epi-
lepsy seen in the Cleveland Clinic Epilepsy Center in a cross-sectional
study exploring the prevalence of sleep disorders and previously
published the prevalence and risk factors of OSA [11]. Enrollment was
completed in 2008. None had been speciﬁcally referred for sleephttp://creativecommons.org/licenses/by-nc-nd/4.0/).
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tients who had: 1) prior history of PSG or known sleep disorder, 2) active
medical or psychiatric conditions that would compromise one's ability to
complete study procedures (recent psychiatric admission or suicide at-
tempt) andnewly diagnosed or progressivemedical conditionnecessitat-
ing frequent follow-up, 3) inability to provide written informed consent
and comply with study procedures, and/or 4) active vagal nerve stimula-
tion therapy were excluded. The Institutional Review Board of the Cleve-
land Clinic approved this study, and participants gave informed consent
before enrollment.
2.2. Structured interviews and completion of a battery of self-assessment
measures
Participants underwent a structured interview to ascertain their
sleep/wake patterns, nocturnal behaviors, sleep/wake disorder symp-
toms, epilepsy characteristics, medical history and medications, and
other substances (alcohol and caffeine quantiﬁed in ounces per week).
The interview was performed by one of the investigators (NFS) board-
certiﬁed in both epilepsy and sleep medicine.
Participants completed a battery of self-reported validated question-
naires which included: 1) ISI to systematically grade presence and se-
verity of insomnia, 2) Epworth Sleepiness Scale (ESS) measuring
subjective daytime sleepiness, and 3) Beck Depression Inventory (BDI)
gauging the likelihood of comorbid depression. Participants completed
a one-week sleep/wake diary prior to PSG. Sleep andwake times, night-
ly awakenings of at least 30min, and seizureswere recorded. Total sleep
duration (TSD)was the average duration of themajor sleep period over
the diary period.
2.3. Comprehensive in-laboratory video-PSG with 18-channel EEG
Participants underwent in-laboratory overnight-attended video-
PSG–EEG to evaluate for OSA. We considered the apnea–hypopnea
index (AHI), a measure of OSA severity, as a covariate in our analysis
becauseOSA is a common comorbidity in patientswith epilepsy [11,12].
Polysomnography recordings included 18 channels of EEG, electro-
oculography (two channels), chin electromyography (EMG; three chan-
nels), leg EMG (four channels), and single-channelmodiﬁed lead II EKG.
Airﬂow and respiration were monitored using nasal pressure transduc-
ers, oronasal thermal sensors and piezoelectric thoracic and abdominal
belts, snore microphone, pulse oximetry, and body position.
Sleep/wake stages, arousals, respiratory events, and other events
were scored using the American Academy of Sleep Medicine (AASM)
scoringmanual rules in place at the time of the analysis [13]. Hypopneas
were deﬁned as a reduction in nasal pressure excursions by ≥50% of
baseline for at least 10 s and associated with a ≥3% oxygen desaturation
or an arousal. Deidentiﬁed PSG studies were interpreted by a
polysomnographer (NFS) blinded to the identity of the patient or
other test results. Apneas and hypopneas were summed to derive the
AHI (mean number of apneas and hypopneas per sleep hour).
2.4. Electronic medical record review
We reviewed data from the Cleveland Clinic electronic medical re-
cord (EMR) speciﬁcally collecting information on: 1) demographics
(age, gender, bodymass index [BMI],marital status, employment status,
and tobacco use); 2) characteristics of the patients epilepsy (epilepsy
syndrome, seizure types, mean monthly seizure frequency excluding
auras, presence of generalized tonic–clonic (GTC) seizures in the
previous 6 months); 3) medications prescribed at the time of enroll-
ment including antiepileptic drugs (AEDs), sedative–hypnotics, psycho-
tropic medications, central nervous system stimulants, and recreational
drugs; 4) comorbid medical disorders; and 5) history of epilepsy
surgery.2.5. Calculation of seizure burden, seizure types, and standardized AED
doses
To more systematically evaluate the impact of seizure type, seizure
burden, and AEDs, we calculated for each patient their seizure burden,
seizure type, and World Health Organization (WHO)-standardized
variable of the amount of AED(s) taken daily to treat their epilepsy
(STD dose) using the Deﬁned Daily Dose, a measure based on the
assumed average daily dose in its main indication for adults [14,15]. We
classiﬁed AEDs as ﬁrst generation, second generation, or combination.
Mean monthly frequency of disabling seizures (excluding auras)
was determined through EMR review and seizure diaries when avail-
able over the 6-month period prior to enrollment and evaluated as a
continuous measure and categorically (seizure-free, b1 seizure per
month, or ≥1 seizures per month). Based upon the structured interview
and EMR and, when available, routine EEG, video-EEG monitoring, and
neuroimaging studies, we classiﬁed each study participant's epilepsy
into generalized, focal temporal lobe epilepsy (TLE), focal extratemporal
(XTLE), or unknown.
2.6. Insomnia Severity Index (ISI)
The Insomnia Severity Index (ISI) is a validated measure for identify-
ing insomnia and grading its severity [10,16–19]. The ISI consists of
seven itemswhich evaluate for difﬁculty falling asleep, difﬁculty staying
asleep, early morning awakenings, satisfaction with the current pattern
of sleep, how it interferes with daily functioning when awake, subjec-
tive awareness of the daytime impairment, and level of distress caused
by it within the past two weeks. Each item is rated on a 5-point scale
with total scores ranging from 0 to 28. A cutoff score of ≥8 on the ISI
has been shown to reliably identify insomnia in patients with cancer
[20]. Another recent study found that the ISI reliably identiﬁed objective
insomnia and showed good correlation with PSG ﬁndings of insomnia
(prolonged sleep latency, lower sleep time, and lower percentage of
REM sleep time) in 151 adults [16]. The ISI was graded as insigniﬁcant
(0–7) or no insomnia, subthreshold/mild insomnia (8–14), or
moderate or severe insomnia (≥15).
The Epworth Sleepiness Scale (ESS) measures a person's recent sub-
jective perception of daytime sleep propensity [21]. Individuals rate
on a 4-point scale (0–3) their chances of dozing off or falling asleep in
eight different real-life common situations or activities. The total ESS
score is the sum of 8-item scores and can range between 0 and 24
with a total score of ≥10 considered abnormal and indicative of
excessive daytime sleepiness (EDS) [22]. The ESS has high test–retest
reliability and internal consistency [22–25].
The Beck Depression Inventory (BDI) is a validated 21-item self-
report questionnaire for depression. The BDI has good test–retest reli-
abilitywith a consistent relationship between the scores and the clinical
state. A score N9 is considered suggestive of depression [26]. A recent
study found that the sensitivity and speciﬁcity of the BDI for the diagno-
sis of depression in 126 adults with epilepsy were around 90% [27]. In
this study, we developed a modiﬁed BDI (mBDI) omitting two items
(16 and 17) that ascertain sleep and wake complaints, in order to
avoid colinearity. Speciﬁcally, item 16 addresses sleep quality, early
morning awakening, and sleep maintenance, and item 17 addresses
tiredness.
2.7. Statistical analysis
The ISI was treated as both a categorical (ISI b 8 for insigniﬁcant, 8 to
b15 for subthreshold/mild, ≥15 for moderate or severe) and a continu-
ous variable. The AHI was classiﬁed into three categories (AHI b 5, 5 to
b10, and ≥10). The ESS (≥10 considered abnormal)was treated as a cat-
egorical variable.
The relationship between continuous variables and the ISI categori-
cal variables was tested using Spearman's rank correlation. The
Table 1
Sample characteristics (N = 90).
Demographics
Age (years) 39.1 ± 12.4
Gender (male) 30 (33.3)
BMI 28.9 ± 7.1
Marital status (married) 39 (49.4)
Employment (employed) 53 (61.6)
Epilepsy type




Generalized epilepsy 22 (24.4)
Unknown 5 (5.6)
Antiepileptic drugs
Number AEDs 1.7 ± 0.8
AED monotherapy 42 (46.7)
1st generation 20 (22.2)
2nd generation 43 (47.8)
Combination 27 (30)
Standardized Dose 2.1 ± 1.6
Seizure burdena
Total seizures/mo 4 ± 7.6
Focal seizures/mo 2.9 ± 7.2
GTCs/mo 1.2 ± 2.9
Seizure-free 26 (28.9)
≥1 seizure/mo 41 (45.6)




Mood disorder 28 (31.1)
Epilepsy surgery 11 (12.2)
Head trauma 20 (22.2)
Other medications and substancesb




Mean± SD for continuous variables; otherwise N (%). AED: antiepileptic drug; GTCs: gen-
eralized tonic–clonic seizures; COPD: chronic obstructive pulmonary disease; mo: month.
a Over prior 6 months.
b Affecting at least 10% of subjects.
Table 2
Agreement between ICSD-2 and ISI for clinically signiﬁcant insomnia.
ISI category
No (b15) Yes (≥15)
ICSD-2 Count Row % Col % Count Row % Col %
No 23 100 35.9 0 0 0
Yes 41 61.2 64.1 26 38.8 100
Kappa = 0.24 (0.13, 0.36). ICSD-2: International Classiﬁcation of Sleep Disorders, 2nd
Edition; ISI: Insomnia Severity Index.
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tested using Welch's two-sample t-test. Tests for difference between
categorical ISI variables and ordinal categorical groups were performed
using Wilcoxon rank–sum test for two categories or Kruskal–Wallis
rank–sum test for greater than two categories.
We categorized study participants as having insomnia according to
the International Classiﬁcation of Sleep Disorders, 2nd Edition (ICSD-2)
[28] based on the sleep interview and analyzed the agreement between
signiﬁcant insomnia as measured by the ISI (ISI ≥ 15) and the ICSD-2
using Cohen's kappa.
The correlations between ISI score and independent variables were
tested using Pearson's product–moment correlation for continuous var-
iables or Spearman's rank correlation for ordinal factors. Finally, the ISI
score was modeled using multiple regressions. Variables included
were chosen based on reaching a 10% level of signiﬁcance in the univar-
iate analyses.
Continuous variables are shown as means with standard deviation,
and categorical variables are shown using counts (%). All analyses
were performed using R software (version 2.15.1, Vienna, Austria). A
signiﬁcance level of p b .05 was the criterion for all tests.
3. Results
3.1. Patient demographics
Ninety subjects (mean age: 39.1 ± 12.4 years; 67% female; mean
BMI: 28.9 ± 7 mm/kg2) completed the study procedures. The epilepsy
type was focal in 63 (70%). Mean seizure frequency (excluding auras)
was 4 ± 7.6 seizures per month. Twenty-six (28.9%) were seizure-free
for the 6-month period before enrollment. Subjects were prescribed a
mean of 1.7 ± 0.8 AEDs. The mean standardized AED dose was 2.1 ±
1.6 per month suggesting a higher-than-average drug burden. Table 1
shows the demographic characteristics of the study population.
3.2. Apnea–Hypopnea Index and Epworth Sleep Scale scores
The AHI on overnight PSG was normal (b5) in 49 (54%), 5 to b10 in
15 (17%), and N10 in 26 (29%). Epworth Sleepiness Scale scores ≥10
endorsing EDS were reported in 31 (34.4%) patients.
3.3. Insomnia Severity Index
The mean Insomnia Severity Index (ISI) score for the group was
10.6 ± 6.7. Thirty-one patients (34.4%) had a score of b8 suggesting
no signiﬁcant insomnia symptoms, 33 (36.7%) had subthreshold/mild
insomnia complaints, and 26 (28.9%) had ISI scores consistentwith a di-
agnosis of moderate or severe insomnia. Table 2 shows results of the
comparison between insomnia classiﬁcation by the ICSD-2 and the ISI
for clinically signiﬁcant insomnia (ISI total ≥ 15). Of the patients
classiﬁed as not having insomnia by the ICSD-2, all were classiﬁed as
not having clinically signiﬁcant insomnia by the ISI. For the 67 patients
who were classiﬁed as having insomnia by the ICSD-2, only 26 (39%)
had an ISI ≥ 15. The two classiﬁcations agreed fairly well on people
with lower and higher levels of insomnia symptoms but disagreed on
how to classify those with intermediate levels of insomnia symptoms.
The proportion of agreement between the ISI and ICSD-2, adjusting for
chance agreement, was 0.24, with 95% CI (0.13, 0.36).
Univariate analysis of the ISI and continuous variables found signiﬁ-
cant relationships only for themBDI (p= .005), BDI (p b .001), and TSD
based on sleep diaries (p= .004) (Supplementary Data Table 1). Signif-
icant univariate relationships were found between ISI severity catego-
ries and categorical variables for comorbid asthma/COPD (p = .003)
and use of sedative–hypnotics (p b .001) (Supplementary Data
Table 2). Comparisons of ISI severity categories on PSG measures
found signiﬁcant differences only for REM latency, with those with
moderate or severe insomnia scores having greater REM latency(Supplementary Data Table 3). No signiﬁcant correlations were found
between total monthly seizure frequency and PSG variables.
Signiﬁcant correlations between ISI and the BDI (r = .32, p = .002),
mBDI (r = .25, p = .021), TSD (r =−0.3, p = .006), and ESS (r = .25,
p = .02) were observed (Table 3). Higher scores on the mBDI, BDI, and
ESS and shorter TSD were signiﬁcantly associated with moderate or
severe insomnia. No signiﬁcant correlations were found for ISI score
and age, BMI, alcohol/caffeine use, or epilepsy-related variables.
Using a ﬁnal multiple regression model (Table 4), we found that
moderate or severe insomnia scores were more likely to be reported
in adults with epilepsy who had decreased TSD (ß = −0.93, p =
.007), head trauma (ß = 4.37, p = .003), sedative–hypnotic use (ß =
4.86, p = .002), AED polytherapy (ß = 3.52, p = .005), and asthma/
Table 3
Correlations between ISI and variables of interest.
Variable Correlation 95% CI p-Value
Age (years) 0.07 −0.14, 0.27 0.51
Body mass index 0.19 −0.02, 0.38 0.076
Modiﬁed Beck Depression Inventory 0.25 0.04, 0.44 0.021
Beck Depression Inventory 0.32 0.12, 0.5 0.002
Epworth Sleepiness Scale 0.25 0.04, 0.43 0.02
Total sleep duration −0.3 −0.48,−0.09 0.006
Alcohol amount (oz/week) −0.1 −0.3, 0.11 0.34
Caffeine amount (oz/week) −0.01 −0.22, 0.2 0.96
Total seizures/moa 0.07 −0.14, 0.27 0.54
GTCs/moa −0.03 −0.24, 0.18 0.77
Number AEDsb 0.13 −0.08, 0.34 0.24
Standardized AED dose 0.13 −0.08, 0.33 0.23
Pearson's product moment correlation unless otherwise indicated. AED: antiepileptic
drug; GTCs: generalized tonic–clonic seizures; mo: month.
a Over prior 6 months.
b Spearman's rank correlation.
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with focal epilepsy identiﬁed a higher mBDI score (ß = 0.24, p =
.015), decreased TSD (ß = −1.11, p = .008), asthma/COPD (ß =
4.19, p= 0.02), and epilepsy surgery (ß=5.33, p= .006) as signiﬁcant
predictors of a higher ISI score. A statistically insigniﬁcant trend for
more severe insomnia was identiﬁed in patients with TLE compared
with those with XTLE (ß =−2.92, p = 0.054).4. Discussion
Systematically employing a validated measure of insomnia [10], we
found that 66% of 90 community-dwelling adults with epilepsy who
were not referred to our epilepsy center for sleep/wake complaints
had an abnormal ISI score consistent with some degree of insomnia,
moderate or severe in 29%. This is a substantially higher prevalence of
insomnia in adults with epilepsy compared with a 25% prevalence of
ISI scores of 8 or more in general adult population studies [29]. In
contrast to the general population, good agreement between the
ICSD-2 diagnostic classiﬁcation for insomnia and ISI scores ≥15 was
found for patients without insomnia and high levels of insomnia
complaints but not for low/intermediate levels of insomnia. Dis-
agreement for low/intermediate levels of insomnia in our study
may be due to the inherent sleep fragmentation and fatigue experi-
enced by this population typically attributed to seizures and AED
therapy. That we found good agreement at the ends of the spectrum
supports the utility of the ISI for identifying signiﬁcant insomnia in
patients with epilepsy.
This high prevalence of insomnia is similar to the few other prospec-
tive studies reported in the medical literature. Vendrame et al. found a
prevalence of moderate or severe insomnia in 55% of 152 adults with
less refractory epilepsy referred to their sleep center [30]. They used
the same criteria for moderate or severe insomnia (ISI ≥ 15) but did
not exclude patients with preexisting insomnia as we did. They foundTable 4
Final regression model of ISI showing signiﬁcant variables for moderate-to-severe
insomnia.
Factor Level Beta 95% CI p-Value
Total sleep duration −0.93 −1.56,−0.27 0.007
Head trauma Yes vs. No 4.37 1.38, 6.96 0.003
Sedative–hypnotic use Yes vs. No 4.86 2.56, 8.65 0.002
AED therapy Poly vs. Mono 3.52 0.14, 5.15 0.005
Asthma/COPD Yes vs. No 3.75 0.24, 6.1 0.014
AED: antiepileptic drug; COPD: chronic obstructive pulmonary disease.that insomnia correlatedwith the number of AEDs and scores of depres-
sion on amodiﬁed version of the BDI-omitting item 16 only (sleep qual-
ity, early morning awakening, and sleep maintenance). Another
prospective study using self-reported questionnaires found that sleep-
maintenance insomnia was more likely to be reported among 100 con-
secutive adults with epilepsy than among 90 controls (52% vs. 34%), al-
though similar percentages of patients with epilepsy and controls
reported sleep-onset insomnia (34% vs. 28%, respectively) [2]. However,
the control group was recruited from hospital staff, whichmay have led
to bias in that study. Forty percent of 165 veterans with epilepsy (87%
male; mean age 56) attending an epilepsy clinic reported insomnia, an
older and predominantly male population, different from ours [31].
In the present study, we neither deﬁned the type of insomnia nor
compared it with a control group; instead, we investigated the severity
of insomnia symptoms using the ISI and its related factors in patients
with epilepsy. We found no signiﬁcant correlations between ISI score
and age, gender, BMI, alcohol/caffeine use, OSA severity, seizure burden,
seizure type, AED type, or AED STD dose, a measure of drug burden. The
only epilepsy variable which increased the likelihood for moderate or
severe insomnia was AED polytherapy, typically considered a marker
of pharmacoresistant epilepsy. Although total drug burden was not a
predictor of moderate or severe insomnia, it is possible that speciﬁc
drugs or drug combinations impact insomnia symptoms. Our sample
was too small to explore themany drug regimens taken by our patients.
While we found signiﬁcant correlations between ISI scores and BDI,
mBDI, and ESS, depressive symptoms, daytime sleepiness, and presence
of OSAwere not predictive of moderate or severe insomnia inmultivar-
iate regression models. Rather, in our ﬁnal model, only TSD, comorbid
asthma/COPD, head trauma, sedative–hypnotic use, and AED
polypharmacy predicted signiﬁcant insomnia symptoms. As expected, re-
duced TSD based on sleep diaries and sedative–hypnotic use, consisting
of nonbenzodiazepine sleep aids, were strongly associatedwith insomnia
symptoms. Studies of insomnia in the general population have similarly
found that insomnia is more prevalent in patients with other medical
disorders including asthma, COPD, and neurological problems including
epilepsy [32].
Depression is the most common comorbid psychiatric disorder
among patients with epilepsy [33,34]. Patients with insomnia were
shown to have signiﬁcantly higher BDI scores than people without in-
somnia in a general population community-based sample [35]. Depres-
sion may be an independent risk factor for insomnia in people with
epilepsy as in the general population. A recent study conﬁrmed that
depression and anxiety in people with epilepsy are associated with
sleep quality, EDS, and increased risk of suicidal ideation and suicide
[36]. Depression in persons with epilepsy also increases the likelihood
of AED nonadherence and reduced quality of life [37]. In our sample,
no association between ISI score and comorbid mood disorder was ob-
served, and neither the BDI nor themBDIwas an independent predictor
of insomnia symptoms in our ﬁnal regression model. Given the high
usage of antidepressant and psychotropic agents, it is possible that
patients with depression in our sample were adequately treated, ren-
dering insomnia symptoms less prevalent. This cross-sectional study
was not designed to explore causal relationships between depression,
its treatments, and sleep/wake complaints.
We further found that a third (34%) of adults with epilepsy in our
study reported EDS based on the ESS. Other studies have found EDS
the second most common sleep/wake complaint in adults with epi-
lepsy [6]. These questionnaire-based studies similar to ours found
that the prevalence of EDS was signiﬁcantly higher in adults with ep-
ilepsy than in age- and gender-matched controls (18% and 28% of
adults with epilepsy vs. 12% and 17% of controls, respectively)
using an ESS cutoff as we did of ≥10 [6]. In addition to the high prev-
alence of EDS, we found a signiﬁcant positive correlation between
the ESS and ISI that is in striking contrast to general population co-
horts with insomnia, where signiﬁcant negative correlations are
generally observed.
31K.I. Yang et al. / Epilepsy & Behavior 60 (2016) 27–32Our study is limited by a cross-sectional design and small sample
size. Selection bias may have contributed to the ﬁndings. Study partici-
pantswere recruited from a tertiary care epilepsy center andweremore
likely to have active epilepsy than patients treated in general neurology
or primary care clinics. Hence, our ﬁndings may not be generalizable to
patients with epilepsy in such clinical settings. Also, we did not investi-
gate the severity of insomnia in relation to individual AEDs. Because of
sample size constraints, we chose to categorize AEDs as either ﬁrst or
second generation and treatment with one or the other or combination
therapy. We know that sleep/wake complaints are commonly attribut-
ed to AED therapy [38]. Detrimental and beneﬁcial effects on sleep
and wakefulness have been reported; however, prospective, random-
ized trials investigating these effects are lacking. Polytherapy with
AEDs was associated with an increased ISI score in the present study,
and this result is comparable with ﬁndings from another recent study
[30]. Finally, with the exception of evaluating for OSA, we did not ana-
lyze whether other primary sleep disorders may have contributed to
the insomnia complaint.
Among the few prior studies exploring insomnia symptoms in
cohorts with epilepsy, our study is unique for several reasons. Firstly,
because OSA ismore common in adultswith epilepsy than in the gener-
al population, we controlled for this comorbidity by recording PSG in all
subjects [11,12]. Secondly, we controlled for AED burden by determin-
ing the standardized AED dose for each subject usingmethodology pub-
lished by the WHO. Thirdly, we modiﬁed the BDI by eliminating two
items that are pertinent in the evaluation of insomnia: sleep quality
and daytime tiredness.
Our study adds to the growing body of literature exploring relation-
ships between sleep and epilepsy. We found that the severity of insom-
nia was not associated with epilepsy itself (save AED polytherapy) but
rather with comorbid conditions, particularly asthma/COPD, head
trauma, and depressive symptoms. The lack of an association between
ISI score and age or gender further suggests that insomnia in patients
with epilepsy may be different than that observed in the general
population, where affected women outnumber men by a factor of two
ormore and symptoms presentwith increasing age [39–41]. These ﬁnd-
ings should be considered in the diagnosis and management of insom-
nia in patients with epilepsy.
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